PCLOF Stock Chart & Stats
$0.06
>-$0.01(-3.20%)
At close: 4:00 PM EDT
$0.06
>-$0.01(-3.20%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.12
Previous CloseN/A
Volume42.60K
Average Volume (3M)9.90K
Market Cap
$9.47M
Enterprise Value$26.82
Total Cash (Recent Filing)$17.52K
Total Debt (Recent Filing)$19.14M
Price to Earnings (P/E)―
Beta-1.77
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,283,630
10 Day Avg. Volume17,743
30 Day Avg. Volume9,897
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Product FocusA focused business model supplying extracts and derivative ingredients into pharmaceutical, wellness and regulated channels supports higher-margin, B2B relationships and product specialization. That structural positioning reduces commodity exposure and can enable long-term contracts and credentialed customers if regulatory approvals and quality controls hold.
Positive Gross Margin And Margin RecoveryA positive ~29% gross margin and material improvement versus prior years indicate product-level economics can be healthy once scale or utilization improves. Durable gross margins imply that, with stable input costs and higher throughput, the company has room to move toward operating leverage and absorb SG&A as sales grow, supporting a pathway to sustainable profitability.
Asset Base IncreasedAn expanding asset base suggests recent investments in capacity, inventory or processing capability. Those tangible investments can support higher output and revenue scalability over months, providing a foundation to convert capacity into sales if market access and regulatory compliance are maintained, improving long-term operating potential.
Bears Say
Negative Equity And High LeverageNegative equity reflects accumulated losses and materially weakens financial flexibility. With roughly $19.1M of debt against negative equity, refinancing risk and creditor pressure rise, limiting capacity to fund operations or invest. This structural solvency issue raises the probability of dilutive financing or restructuring over the medium term.
Persistent Cash BurnSustained negative operating and free cash flow indicate the business consumes real cash to run operations. Even with some improvement versus earlier years, ongoing burn necessitates external capital to maintain operations, increasing dilution or debt burdens and reducing time available to achieve profitable scale before liquidity constraints force structural changes.
Sharp Revenue Contraction And Deep LossesA tiny and rapidly contracting revenue base combined with steep negative EBIT and net margins undermines the firm's ability to achieve operating leverage. Structural recoveries require rebuilding demand and improving cost structure; until revenue stabilizes at larger scale, margin recovery may be fragile and reliant on successful execution of commercial strategies.
PharmaCielo News
PCLOF FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was <$0.01 and its highest was $0.12 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is $9.47M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Aug 14, 2026 which is in 7 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 211,283,630 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in PCLOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Ownership Overview
14.65% Insiders
0.15% Other Institutional Investors
85.06% Public Companies and
Individual Investors